Skip to main content
Eupraxia Pharmaceuticals Inc. logo

Eupraxia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · EPRX ISIN · CA29842P1053 TSX Manufacturing
Open in API
Filings indexed 226 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country CA Canada
Listing TSX EPRX

About Eupraxia Pharmaceuticals Inc.

https://eupraxiapharma.com/

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing targeted, extended-release therapies using its proprietary drug delivery platform, Diffusphere™. This technology is engineered to optimize local, controlled drug delivery directly to diseased tissues, aiming to maximize efficacy and minimize systemic side effects. Eupraxia addresses therapeutic areas with significant unmet medical needs, particularly in gastrointestinal and musculoskeletal diseases. The company's lead product candidate, EP-104GI, is currently in Phase 2 clinical trials for the treatment of Eosinophilic Esophagitis (EoE), a chronic inflammatory disease of the esophagus. The Diffusphere platform is designed to potentially offer long-term relief with fewer doses across various conditions, including inflammatory diseases, oncology, and pain.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing scientific presentations at a medical conference and an associated investor event, with no actual financial results, regulatory form references, or detailed investor slide decks attached. It does not constitute an actual investor presentation (IP) deck, nor a formal regulatory filing under any specific category. It also is not a report announcement (RPA), dividend notice, etc. Therefore it falls into the general “Regulatory Filings” fallback bucket for miscellaneous announcements.
2026-04-22 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a press release announcing Eupraxia’s presentations at a scientific conference (Digestive Disease Week) and a virtual investor event. It is not an earnings release, a financial report, a proxy solicitation, nor actual investor presentation materials; it simply provides event details and corporate background. This does not fit any more specific category, so it falls under the general “Regulatory Filings” fallback.
2026-04-22 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release announcing Questor’s fourth quarter and full-year 2025 financial results, providing key revenue, EBITDA, profit/loss figures, highlights, president’s message, and forward-looking statements. It summarizes financial performance and refers investors to the full audited statements and MD&A on the website, rather than containing the full report itself. This format and content align with an Earnings Release (ER). FY 2025
2026-04-21 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing Phase 1b/2a clinical trial data (36-week tissue health and symptom response results) for Eupraxia’s RESOLVE trial. It contains no financial earnings metrics, no board or management changes, no dividend or voting results, no audit, legal, M&A or capital-raising details, and is not an attached investor presentation or report publication notice. As a general corporate announcement of trial results, it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-21 English
News release - English.pdf
Investor Presentation Classification · 1% confidence The document is a press release announcing that management will present at upcoming investor conferences, with dates, formats, and webcast details. It is an announcement of investor presentations rather than financial results or regulatory filings, matching the definition of an Investor Presentation (IP).
2026-04-15 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing that the company’s management will present at upcoming investor conferences. It does not contain financial results (so it is not an Earnings Release), nor is it an actual Investor Presentation deck or a detailed report (so it is not IR/10-K/MDA/IP). It is also not a regulatory filing under a specific SEC form, nor does it relate to dividends, shares, M&A, or board changes. Therefore it falls into the fallback category “Regulatory Filings” (RNS) for miscellaneous announcements that do not fit other specific categories.
2026-04-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.